ASH Clinical News December 2015 | Page 65

FOR THE TREATMENT OF ADULTS WITH NEWLY DIAGNOSED Ph+ CML-CP AND ADULTS WITH RESISTANT OR INTOLERANT Ph+ CML-CP/AP TAKE ON Ph+ CML Help patients reach their treatment goals with TASIGNA® (nilotinib) ‘‘ I relied on the skyhook. ‘‘ InIn basketball, treating my Ph+ CML, I rely on TASIGNA. - KA